Don’t miss the Best of GU & GI Cancers Conference 2026.
📅 April 17, 2026
Expert-led updates in GU & GI oncology
Clinical insights you can apply immediately
Register now:
https://bit.ly/3OvjDC4
#GUCancers #GICancers #Oncology
Gut microbiota derived metabolites strongly impact GI cancers
enhancing chemo sensitivity while also driving resistance and mucositis.
📍Global Microbiome Congress (GMC 2026)
🗓️ June 15–16 | 🌍 Hybrid: Boston & Virtual
🔗 microbiomecongress.org
#MicrobiomeScience #GICancers #PrecisionOncology
Coming up at #GI26, Dr. Geoffrey Ku will give a medical oncologist's perspective on the role of local and systemic treatments in metastatic #gastriccancer and #gastroesophagealcancer @mskcancercenter.bsky.social #GICancers @ascocancer.bsky.social
3:45 – 5 p.m. PST | Level 3, Room 3001
Join Rachna Shroff, MD, MS, FASCO at an ASCO GI 2026 satellite symposium exploring HER2-positive GI cancers, from molecular testing to targeted therapy across gastric/GEJ, CRC, and biliary tract cancers.
👉 Register: https://bit.ly/48FksQl
#ASCOGI2026 #HER2 #GICancers
Surgical oncologist Aslam Ejaz, MD, MPH, has been named co-leader of the Translational Oncology (TO) Research Program at the Cancer Center.
Ejaz is Chief of Surgical Oncology at UI Health, specializing in #GICancers.
Read more: bit.ly/4hjxyW2
Results were presented at #ESMO25 from phase III #ClinicalTrials that highlighted both progress and ongoing challenges in the treatment of HER2-positive upper #GICancers.
Read more in the #ESMODailyReporter 🔗 https://ow.ly/SF7J50Xe3nK
![Screening for Financial Toxicity and Health-Related Social Risks in Patients With Gl Cancer: Results From a Large
Cancer Center
PURPOSE Patients with GI cancers often face significant financial toxicity (FT) and
health-related social risks (HRSRs), yet best practices for screening remain unclear. This study aimed to evaluate the prevalence of FT and HRSR and identify associated factors.
METHODS From June 2022 to August 2023, patients were screened using the Compre-hensive Score for Financial Toxicity (COST), patient-reported HRSR (eg, housing, food insecurity), and quality of life (QOL). Multivariate regressions were used to assess predictors of FT and HRSR, adjusting for several variables.
RESULTS Among 8,335 patients with GI cancer, 45% had a COST score of <26, indicating FT. In adjusted linear regression, FT was associated with racial/ethnic minority status (B, 4.20; P < .001), advanced disease (stage III (B, 1.33; P < .001); IV [B,
1.56; P < .001)), recent treatment (B, 3.23; P < .001), and anal (B, 1.97; P = .003),
esophageal (B, 1.66; P = .005), or hepatobiliary cancer (B, 1.05; P = .031). Older
age (≥65 years [B, -5.17; P < .001)), higher income ($100,000-$200,000 (B, -181; P < .001); >$200,000 [B, -3.80; P < .001)), and private insurance (B, -1.70; P < .001) were protective. Twenty-eight percent reported at least one HRSR. HRSRs were associated with minority status (odds ratio [OR], 2.14;
P < .001), advanced disease (stage III [OR, 1.31; P = .001); IV[OR, 1.24; P = .010)),
recent treatment (OR, 1.20; P = .001), and gastric cancer (OR, 1.25; P = .027).
Lower HRSR was associated with older age (OR, 0.59; P < .001), higher income ($100,000-$200,000 (OR, 0.66; P < .001); >$200,000 (OR, 0.48; P < .001)), and private insurance (OR, 0.64; P < .001). Sex was not a predictor. Worst FT was associated with decreased QOL (B, -0.98; P < .001) and reduced medication adherence (B, 0.11; P < .001).
CONCLUSION High levels of FT and HRSR were observed in patients with GI ca…](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:bezfqro7gz4mmrf3yx5wi7gn/bafkreigrnqgkbag2uonhhredzkyqn5kx4ofbrccmoxznu2gaefaai3m3vq)
Screening for Financial Toxicity and Health-Related Social Risks in Patients With Gl Cancer: Results From a Large Cancer Center PURPOSE Patients with GI cancers often face significant financial toxicity (FT) and health-related social risks (HRSRs), yet best practices for screening remain unclear. This study aimed to evaluate the prevalence of FT and HRSR and identify associated factors. METHODS From June 2022 to August 2023, patients were screened using the Compre-hensive Score for Financial Toxicity (COST), patient-reported HRSR (eg, housing, food insecurity), and quality of life (QOL). Multivariate regressions were used to assess predictors of FT and HRSR, adjusting for several variables. RESULTS Among 8,335 patients with GI cancer, 45% had a COST score of <26, indicating FT. In adjusted linear regression, FT was associated with racial/ethnic minority status (B, 4.20; P < .001), advanced disease (stage III (B, 1.33; P < .001); IV [B, 1.56; P < .001)), recent treatment (B, 3.23; P < .001), and anal (B, 1.97; P = .003), esophageal (B, 1.66; P = .005), or hepatobiliary cancer (B, 1.05; P = .031). Older age (≥65 years [B, -5.17; P < .001)), higher income ($100,000-$200,000 (B, -181; P < .001); >$200,000 [B, -3.80; P < .001)), and private insurance (B, -1.70; P < .001) were protective. Twenty-eight percent reported at least one HRSR. HRSRs were associated with minority status (odds ratio [OR], 2.14; P < .001), advanced disease (stage III [OR, 1.31; P = .001); IV[OR, 1.24; P = .010)), recent treatment (OR, 1.20; P = .001), and gastric cancer (OR, 1.25; P = .027). Lower HRSR was associated with older age (OR, 0.59; P < .001), higher income ($100,000-$200,000 (OR, 0.66; P < .001); >$200,000 (OR, 0.48; P < .001)), and private insurance (OR, 0.64; P < .001). Sex was not a predictor. Worst FT was associated with decreased QOL (B, -0.98; P < .001) and reduced medication adherence (B, 0.11; P < .001). CONCLUSION High levels of FT and HRSR were observed in patients with GI ca…
Clothing Repairs to Home Food Medications Housing Transportation 0% 9% 11% 11% 12% 12% Proportion of Patients (%, N = 8,335) FIG 1. HRSRs among patients with Gl cancers. Proportion of patients with Gl cancer who self-reported difficulty in affording at least one essential need and were identified as having a specific HRSRs. HRSR, health-related social risks.
In this analysis of >8k with #GIcancers:
👉45% (n=3,764) had a COST score of <26, indicating #financialToxicity
👉28% (n=2,321) reported at least 1 health related social risk... including > 1️⃣in🔟 who couldn't afford 🍔🥗, 🛏️🏡, or 🚗🚐
@ascocancer.bsky.social
ascopubs.org/doi/pdfdirect/10.1200/OP-25-00218
Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework
➡️ buff.ly/1f4BUiT
#Epigenetics #GIcancers #DNAmethylation
SCI member Ruijiang Li & others found that the pathology foundation model accurately predicts survival outcomes in #GICancers and complements clinicopathologic factors, which may improve risk stratification and guide personalized adjuvant therapy. ascopubs.org/doi/abs/10.1... #AIhealth
Thrilled to have #friend & #collaborator
@KaiKeenShiu of @ucl.ac.uk 🇬🇧 visit us in #hongkong 🇭🇰 these last few days, including a visit & talk specifically
@cuhkmedicine.bsky.social this afternoon.
Good to familiarise myself with updates in #GICancers as well!
@StephenLChan1 @mollylisc #KaOnLam
Dr. Samuel Butensky highlights the barriers patients with #GICancers face, including transportation issues, financial strains, and limited access to mental health support & medications. #SSO2025
@socsurgonc.bsky.social @yaleschoolofmed.bsky.social
@thelancet.bsky.social the Lancet summit for cancer control in China 🇨🇳
Great discussion for #breastcancer #lungcancer #GIcancers
So grateful 🙏🙏 for this news to end #2024 !
Thankful to the #CUCancerCenter for funding our grant - and look forward to continuing our work for early #GICancers !
Special thanks to #JenniferChristie & #SachinWani for their support and mentorship !
@cugastrohep.bsky.social
Australian research links unhealthy diets to deadly cancers yespunjab.com?p=68824
#Australia #GastrointestinalCancer #HealthyDiet #FlindersUniversity #GIcancers #BowelCancer #DigestiveHealth #FibreIntake #CancerPrevention #HealthyEating #ResearchStudy #FoodAndHealth
We're excited to introduce our new @CancerResearchUK.org #PhD student Nefeli Taravira!
Nefeli joins us to focus on the screening & surveillance of #GICancers.
Her important work will strengthen our #CancerResearch team! Welcome, Nefeli!
